Cargando…

T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia

BACKGROUND: Acute myeloid leukemia (AML) remains one of the most challenging hematological malignancies. Despite progress in therapeutics, majority of patients succumb to this neoplasm. CD33 is a proven therapeutic target, given its expression on most AML cells. Almost all anti-CD33 antibodies targe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hoseini, Sayed Shahabuddin, Vadlamudi, Mallika, Espinosa-Cotton, Madelyn, Tran, Hoa, Feng, Yi, Guo, Hong-fen, Xu, Hong, Cheung, Irene, Cheung, Nai-Kong V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8154967/ https://www.ncbi.nlm.nih.gov/pubmed/34035113 http://dx.doi.org/10.1136/jitc-2021-002509

Ejemplares similares

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2020)

Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody
por: Park, Jeong A, et al.
Publicado: (2023)

A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL
por: Mehta, Naveen K, et al.
Publicado: (2022)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2017)

Histone H3.3 promotes IgV gene diversification by enhancing formation of AID‐accessible single‐stranded DNA
por: Romanello, Marina, et al.
Publicado: (2016)

AID–RNA polymerase II transcription-dependent deamination of IgV DNA
por: Pham, Phuong, et al.
Publicado: (2019)

Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2
por: Pellizzari, Giulia, et al.
Publicado: (2021)

A polymorphism of the TIM-1 IgV domain: Implications for the susceptibility to filovirus infection
por: Kuroda, Makoto, et al.
Publicado: (2014)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies
por: Poussin, Mathilde, et al.
Publicado: (2021)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

Site-to-site cross-talk in OST-B glycosylation of hCEACAM1-IgV
por: Williams, Robert V., et al.
Publicado: (2022)

Cloning and identification of the CTLA-4IgV gene and functional application of vaccine in Xinjiang sheep
por: Kong, Huifang, et al.
Publicado: (2022)

The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity
por: Saha, Shrayasee, et al.
Publicado: (2023)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
por: van Diest, Eline, et al.
Publicado: (2021)

P059: Multi-effector cell targeting with half-life extended bispecific scFv in Hodgkin lymphoma
por: Shi, Zhiyuan, et al.
Publicado: (2022)

Identification of immunotherapy and radioimmunotherapy targets on desmoplastic small round cell tumors
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2023)

The eIg technology to generate Ig-like bispecific antibodies
por: Kühl, Lennart, et al.
Publicado: (2022)

Anti-GD2 IgA kills tumors by neutrophils without antibody-associated pain in the preclinical treatment of high-risk neuroblastoma
por: Evers, Mitchell, et al.
Publicado: (2021)

First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach
por: Schaller, Teilo H, et al.
Publicado: (2020)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
por: Luke, Jason J, et al.
Publicado: (2021)

JAK and mTOR inhibitors prevent cytokine release while retaining T cell bispecific antibody in vivo efficacy
por: Leclercq, Gabrielle, et al.
Publicado: (2022)

GENETICS OF A NEW IgV(H) (T15 IDIOTYPE) MARKER IN THE MOUSE REGULATING NATURAL ANTIBODY TO PHOSPHORYLCHOLINE
por: Lieberman, R., et al.
Publicado: (1974)

Immunotherapy and Radioimmunotherapy for Desmoplastic Small Round Cell Tumor
por: Espinosa-Cotton, Madelyn, et al.
Publicado: (2021)

igv.js: an embeddable JavaScript implementation of the Integrative Genomics Viewer (IGV)
por: Robinson, James T, et al.
Publicado: (2022)

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade
por: Jeong, Seongju, et al.
Publicado: (2021)

Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth
por: Chen, Xin, et al.
Publicado: (2020)

Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity
por: Chen, Shih-Hsun, et al.
Publicado: (2021)

Src/lck inhibitor dasatinib reversibly switches off cytokine release and T cell cytotoxicity following stimulation with T cell bispecific antibodies
por: Leclercq, Gabrielle, et al.
Publicado: (2021)

Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate
por: Waaijer, Stijn JH, et al.
Publicado: (2020)

Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
por: Dang, Kevin, et al.
Publicado: (2021)

Deciphering molecular and cellular ex vivo responses to bispecific antibodies PD1-TIM3 and PD1-LAG3 in human tumors
por: Natoli, Marina, et al.
Publicado: (2022)

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
por: Hägerbrand, Karin, et al.
Publicado: (2022)

Single Nucleotide Variants of the Human TIM-1 IgV Domain with Reduced Ability to Promote Viral Entry into Cells
por: Hattori, Takanari, et al.
Publicado: (2022)

Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release
por: Aschmoneit, Nadine, et al.
Publicado: (2021)

Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
por: Yi, Ming, et al.
Publicado: (2022)

Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and CTLA-4 in patients with advanced solid tumors
por: Ma, Yuxiang, et al.
Publicado: (2023)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Acute myeloid leukemia targets for bispecific antibodies
por: Hoseini, S S, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fr41s6ejspt011o6068g3s1pt7